Literature DB >> 1642831

Simultaneous chemoradiation in the treatment of advanced head and neck cancer.

M C Weissler1, S Melin, S L Sailer, B F Qaqish, J G Rosenman, H C Pillsbury.   

Abstract

Fifty-eight patients with either advanced or unresectable squamous cell carcinoma of the head and neck were randomly selected to receive either twice daily radiation alone or twice daily radiation plus concomitant chemotherapy with cisplatin and fluorouracil (5-fluorouracil). There was no advantage in survival or time to progression with the addition of chemotherapy to twice daily radiation for patients with advanced resectable cancers. In the group of patients with unresectable cancers, however, there was a statistically significant advantage to the addition of chemotherapy, both in terms of disease-free survival and date to progression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1642831     DOI: 10.1001/archotol.1992.01880080028008

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  8 in total

Review 1.  Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region.

Authors:  Amanda Psyrri; George Fountzilas
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  The influence of field size and other radiotherapy parameters on acute toxicity in pharyngolaryngeal cancers.

Authors:  R Miralbell; A S Allal; B Mermillod; B Pastoors
Journal:  Strahlenther Onkol       Date:  1999-02       Impact factor: 3.621

Review 3.  Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Authors:  Ambika Parmar; Michaelina Macluskey; Niall Mc Goldrick; David I Conway; Anne-Marie Glenny; Janet E Clarkson; Helen V Worthington; Kelvin Kw Chan
Journal:  Cochrane Database Syst Rev       Date:  2021-12-20

4.  Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study.

Authors:  George Fountzilas; Elisabeta Ciuleanu; Urania Dafni; George Plataniotis; Anna Kalogera-Fountzila; Epaminontas Samantas; Eleni Athanassiou; John Tzitzikas; Tudor Ciuleanu; Angelos Nikolaou; Panayiotis Pantelakos; Thomas Zaraboukas; Nikolaos Zamboglou; John Daniilidis; Nicolas Ghilezan
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

5.  Metastatic squamous cell carcinoma neck with occult primary: A retrospective analysis.

Authors:  Pragya Shukla; Deepak Gupta; Shyam Singh Bisht; Mohan Chand Pant; Madan Lal Bhatt; Kirti Srivastava; Mahendra Pal Singh Negi
Journal:  Indian J Med Paediatr Oncol       Date:  2009-10

6.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.

Authors:  Benjamin Lacas; Alexandra Carmel; Cécile Landais; Stuart J Wong; Lisa Licitra; Jeffrey S Tobias; Barbara Burtness; Maria Grazia Ghi; Ezra E W Cohen; Cai Grau; Gregory Wolf; Ricardo Hitt; Renzo Corvò; Volker Budach; Shaleen Kumar; Sarbani Ghosh Laskar; Jean-Jacques Mazeron; Lai-Ping Zhong; Werner Dobrowsky; Pirus Ghadjar; Carlo Fallai; Branko Zakotnik; Atul Sharma; René-Jean Bensadoun; Maria Grazia Ruo Redda; Séverine Racadot; George Fountzilas; David Brizel; Paolo Rovea; Athanassios Argiris; Zoltán Takácsi Nagy; Ju-Whei Lee; Catherine Fortpied; Jonathan Harris; Jean Bourhis; Anne Aupérin; Pierre Blanchard; Jean-Pierre Pignon
Journal:  Radiother Oncol       Date:  2021-01-27       Impact factor: 6.280

7.  Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment.

Authors:  Vishal M Bulsara; Helen V Worthington; Anne-Marie Glenny; Janet E Clarkson; David I Conway; Michaelina Macluskey
Journal:  Cochrane Database Syst Rev       Date:  2018-12-24

8.  A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.

Authors:  W Budach; T Hehr; V Budach; C Belka; K Dietz
Journal:  BMC Cancer       Date:  2006-01-31       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.